FDA 510(k) clearances for chronic pain devices: regulatory trends and safety outcomes from 1976–2025

We characterized regulatory and safety patterns of FDA 510(k)-cleared chronic pain devices over five decades.
We analyzed 1718 chronic pain devices cleared from 1976–2025, assessing device modality, review times, recalls (2002–2025), and market concentration (Herfindahl – Hirschman Index, HHI).
Most devices were noninvasive neuromodulation (1,486 [86.5%]), followed by invasive neuromodulation (162 [9.4%]), energy-based (67 [3.9%]), and digital therapeutics (3 [0.2%]). Median FDA review was 117 days (IQR, 69–220) – shorter for invasive (90 days; IQR, 42–156) than noninvasive neuromodulation (120 days; IQR, 70–222). US-origin devices declined from 97.6% (1976–1985) to 43.1% (2016–2025). Invasive devices declined 45% from peak (12.3%, 1996–2005) to 6.7% (2016–2025), while digital therapeutics emerged post-2016. Among 843 devices evaluated for safety, invasive devices had 14-fold higher recall rates than noninvasive (100 vs. 7.1 per 1000); median time to recall was 3.9 years (IQR, 2.9–4.7). Market concentration differed markedly: invasive devices highly concentrated (HHI, 3710; single manufacturer 58%) versus fragmented noninvasive markets (HHI, 43).
Despite shorter regulatory review, invasive chronic pain devices demonstrated substantially higher recall rates. The shift toward globally sourced noninvasive technologies reflects evolving regulatory-technological considerations.